CHICAGO--(BUSINESS WIRE)--Gamma Medica today announces the company will now offer Philips MicroDose SI, the first full-field digital mammography (FFDM) system that supports single-shot, non-invasive spectral imaging, as a complement to its market leading LumaGEM Molecular Breast Imaging (MBI) system. LumaGEM is a highly effective and cost-efficient technology for detecting breast cancer in patients with complex mammograms and dense breast tissue. The agreement with Philips will enable Gamma Medica to provide breast imaging suites with the option to purchase both technologies and offer the most advanced and safest commercially available dense breast solution for women. Philips will continue selling MicroDoseSI directly to customers.
Philips MicroDose mammography SI delivers outstanding image quality and non-invasive spectral applications in one fast and comfortable low-dose mammogram.
For those forty percent of U.S. women who have dense breast tissue and those who have received inconclusive mammography results, the LumaGEM used as a secondary imaging tool is highly sensitive in its ability to detect lesions as small as five millimeters. As a functional imaging modality, it is also highly specific, resulting in fewer “false positives” and higher true positive biopsy rates compared to anatomical imaging methods such as ultrasound and MRI.
Breast tissue density has been linked to an increased risk of breast cancer and also decreases the sensitivity of mammography which impacts early detection. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as dense tissue masks the appearance of tumors.
“Gamma Medica is very excited to be working closely with Philips in an effort to provide women with the best technology options for breast cancer screening. Together, the LumaGEM and Philips MicroDose SI are the solution for increasing patient satisfaction and improving patient outcomes while lowering the overall cost of breast cancer treatment,” said Jim Calandra, president and chief executive officer of Gamma Medica. “The opportunity for imaging suites to have two leading breast cancer detection technologies under one roof will help revolutionize the future of breast cancer care.”
“Like Philips, Gamma Medica has taken a proactive approach to the growing industry demand and increasing regulatory pressure for low dose solutions,” said Richard Fabian, vice president, Imaging Systems Marketing, of Philips Healthcare. “MicroDose SI is just one of a range of Philips low-dose solutions that provide clinicians with the data and insights they need to make a definitive diagnosis while avoiding unnecessary exposure to radiation.”
Gamma Medica’s LumaGEM MBI system and Philips MicroDose SI will be on display at Gamma Medica’s booth, #1729 South Hall, during the 100th annual meeting of the Radiological Society of North America (RSNA), November 30th – December 5th in Chicago.
About Gamma Medica, Inc.
Gamma Medica, Inc. is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company designs, builds and services the LumaGEM® MBI system, the first commercially available, FDA-cleared planar, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular breast imaging. For more information, visit www.gammamedica.com.